Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

A NEW TECHNIQUE FOR TREATING HEMORRHAGIC SHOCK

Award Number: R43HL114235
ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 04/19/2012
PERIOD OF PERFORMANCE END DATE: 03/31/2015

Group Awards By:

View Award Description

A NEW TECHNIQUE FOR TREATING HEMORRHAGIC SHOCK - DESCRIPTION (provided by applicant): The specific aims of this proposal are to use a newly developed intracellular energy delivery technique to enhance resuscitation, and to study the relationship between tissue high-energy phosphate supplementation and tissue necrosis and apoptosis during hemorrhagic shock. In most western countries, trauma/hemorrhage is the leading cause of death up to the age of 40. The most common consequence of severe trauma and hemorrhage is shock, which is a hypovolemic condition in which oxygen delivery to the body is inadequate for the generation of the adenosine triphosphate (ATP) and adenosine diphosphate (ADP) necessary to maintain the function and structural integrity of tissues. Treatment strategies for shock have changed very little in the past half century and the incidence of mortality and morbidity remains very high. Depletion of high-energy phosphates during hemorrhagic shock was described decades ago, and direct administration of free Mg-ATP was reported to increase tissue ATP concentrations, tissue and mitochondrial Mg levels, and cellular functions by some authors. However, this approach is controversial, not only because the protective effects cannot always be duplicated by other scientists, but also because the half life of ATP is very short in the blood circulation-less than 40 seconds. Furthermore, it i well known that highly charged molecules like ATP do not normally cross the cell membrane. We have developed a technique for intracellular Mg-ATP delivery (named ATP- vesicles or VitaSolTM). Preliminary results have indicated a very promising effect in several models of tissue hypoxia and ischemia, including shock. Our hypothesis is that the replenishment of intracellular ATP levels alleviates or eliminates many of the detrimental effects caused by hemorrhagic shock, thereby increasing survival time. This Phase I proposal has two aims: 1) To establish the effect of VitaSolTM treatment on hemorrhagic shock; and 2) To investigate the relationship between tissue high- energy phosphate contents and necrosis and apoptosis during hemorrhagic shock, and the effect of VitaSolTM treatment on these changes. These studies have not been performed in the past. The success of this project will likely provide a totally new therapeutic approach for treatment of severe trauma and shock. Further study of this new energy delivery technique may also benefit various clinical conditions, such as coronary heart disease, stroke, spinal cord injury, cardiopulmonary bypass, organ transplant, chronic wounds, and many other conditions where ischemia is involved. The potential impact on medicine is high.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2013 ( Subtotal = $199,990 )
2013	2013	NOVERATECH LLC	201 EAST JEFFERSON STREET	LOUISVILLE	KY	40202	JEFFERSON	USA	Blood Diseases and Resources Research	000	2	4/24/2013	NON-COMPETING CONTINUATION	$179,991
2013	2013	NOVERATECH LLC	201 EAST JEFFERSON STREET	LOUISVILLE	KY	40202	JEFFERSON	USA	Blood Diseases and Resources Research	001	2	7/26/2013	NON-COMPETING CONTINUATION	$19,999
														Subtotal = $199,990

Issue Date FY: 2012 ( Subtotal = $199,825 )
2012	2012	NOVERATECH LLC	201 EAST JEFFERSON STREET	LOUISVILLE	KY	40202	JEFFERSON	USA	Blood Diseases and Resources Research	000	1	4/19/2012	NEW	$199,825
														Subtotal = $199,825

Grand Total All Awards = $399,815

Top

All Categories

About

Search

Reports

Data Submission

Award Information

A NEW TECHNIQUE FOR TREATING HEMORRHAGIC SHOCK

Award Number: R43HL114235

ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 04/19/2012

PERIOD OF PERFORMANCE END DATE: 03/31/2015

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer